Alnuctamab

阿奴卡妥单抗

Report date: 2026/04/22 20:01:10

Base Information

Drug NameAlnuctamab
Drug Alias NameALNUCCC-93269EM-901BMS-986349
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsB-cell maturation protein modulators
TargetsT cell surface glycoprotein CD3B-cell maturation protein
Therapy Area/IndicationsLupus Erythematosus, SystemicMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEngmab Ag
China Registration ClassN/A

Develop Information

Active CompaniesCelgene International Ii SarlBristol-Myers Squibb (China) Investment Co LtdIcahn School Of Medicine At Mount Sinai
Inactive CompaniesCelgene Corp
Active IndicationsLupus Erythematosus, SystemicMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A